Dapsone gel - verum

PreclinicalSmall molecule

CCook County Health

Dapsone gel - verum is one of 7 small molecule programs targeting Prurigo. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PrurigoActive, not recruiting

PrurigoPreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Prurigo

#DrugCompanyPhaseTrials

Jakafi

Incyte

Approved

—2

Kenalog

BBausch Health Americas, Inc.

Phase 3

1 3

Fasenra

AstraZeneca

Phase 2

—4

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 5

Rezzayo

Roche

Preclinical

—6

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Dapsone gel - verum

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prurigo1 trial

Dapsone Prurigo Study

Unknown status·CCook County Health·N/A·NCT01870050·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dapsone gel - verum. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dapsone gel - verum compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dapsone gel - verum. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cook County Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCook County Health

Dapsone gel - verum

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prurigo1 trial

References

Drug Info

Quick Facts

Related News